NASDAQ:EPZMEpizyme Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Epizyme Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $16.83 +1.78 (+11.83 %) (As of 04/9/2020 02:37 AM ET) Add Compare Share Today's Range$15.12Now: $16.83▼$16.9950-Day Range$13.68MA: $18.75▼$25.4852-Week Range$9.73Now: $16.83▼$27.82Volume1.23 million shsAverage Volume1.14 million shsMarket Capitalization$1.70 billionP/E RatioN/ADividend YieldN/ABeta2.34 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer. In addition, the company is developing EZM8266, a G9a inhibitor that is in the Phase 1 study for the treatment of sickle cell disease; pinometostat, which is in the preclinical studies stage for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor that is in Phase II clinical trial for patients with solid tumors and NHL; and PRMT1 inhibitor, which is in the Phase 1 clinical trial. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Study Association; and Eisai Co. Ltd. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingEpizyme has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.57, Epizyme has a potential upside of 81.6% from its current price of $16.83.Amount of Analyst CoverageEpizyme has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.8 Community Rank Outperform VotesEpizyme has received 465 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEpizyme has received 361 “underperform” votes. (Add your “underperform” vote.)Community SentimentEpizyme has received 56.30% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote “Outperform” if you believe EPZM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEpizyme does not currently pay a dividend.Dividend GrowthEpizyme does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Epizyme insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $391,749.00 in company stock.Percentage Held by InsidersOnly 16.60% of the stock of Epizyme is held by insiders.Percentage Held by Institutions90.70% of the stock of Epizyme is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Epizyme are expected to decrease by -25.53% in the coming year, from ($2.82) to ($2.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Epizyme is -8.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Epizyme is -8.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEpizyme has a P/B Ratio of 5.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.65 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EPZM Previous Symbol CUSIPN/A CIK1571498 Webhttp://www.epizyme.com/ Phone617-229-5872Debt Debt-to-Equity Ratio0.14 Current Ratio11.61 Quick Ratio11.61Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$23.80 million Price / Sales71.26 Cash FlowN/A Price / Cash FlowN/A Book Value$3.22 per share Price / Book5.23Profitability EPS (Most Recent Fiscal Year)($1.93) Net Income$-170,290,000.00 Net Margins-715.53% Return on Equity-58.26% Return on Assets-44.15%Miscellaneous Employees124 Outstanding Shares100,771,000Market Cap$1.70 billion Next Earnings Date5/4/2020 (Estimated) OptionableOptionable Receive EPZM News and Ratings via Email Sign-up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:EPZM Rates by TradingView Epizyme (NASDAQ:EPZM) Frequently Asked Questions How has Epizyme's stock been impacted by COVID-19 (Coronavirus)? Epizyme's stock was trading at $18.46 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EPZM shares have decreased by 8.8% and is now trading at $16.83. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Epizyme? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Epizyme. When is Epizyme's next earnings date? Epizyme is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Epizyme. How were Epizyme's earnings last quarter? Epizyme Inc (NASDAQ:EPZM) released its quarterly earnings results on Monday, February, 24th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.08. The biopharmaceutical company had revenue of $4.29 million for the quarter, compared to analyst estimates of $2.83 million. Epizyme had a negative return on equity of 58.26% and a negative net margin of 715.53%. View Epizyme's earnings history. What price target have analysts set for EPZM? 7 Wall Street analysts have issued 12-month target prices for Epizyme's stock. Their forecasts range from $16.00 to $36.00. On average, they anticipate Epizyme's share price to reach $30.57 in the next twelve months. This suggests a possible upside of 81.6% from the stock's current price. View analysts' price targets for Epizyme. Has Epizyme been receiving favorable news coverage? Headlines about EPZM stock have been trending very negative on Thursday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Epizyme earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutEpizyme. Are investors shorting Epizyme? Epizyme saw a decrease in short interest during the month of March. As of March 13th, there was short interest totaling 7,083,200 shares, a decrease of 6.3% from the February 27th total of 7,560,000 shares. Based on an average trading volume of 928,800 shares, the days-to-cover ratio is currently 7.6 days. Currently, 8.7% of the shares of the stock are sold short. View Epizyme's Current Options Chain. Who are some of Epizyme's key competitors? Some companies that are related to Epizyme include Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Reata Pharmaceuticals (RETA), Forty Seven (FTSV), United Therapeutics (UTHR), Global Blood Therapeutics (GBT), Evotec (EVTCY), Nektar Therapeutics (NKTR), Blueprint Medicines (BPMC), Mirati Therapeutics (MRTX), Emergent Biosolutions (EBS) and FibroGen (FGEN). What other stocks do shareholders of Epizyme own? Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Amarin (AMRN), Crispr Therapeutics (CRSP), Micron Technology (MU), Clovis Oncology (CLVS), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Sangamo Therapeutics (SGMO), Verastem (VSTM), Intercept Pharmaceuticals (ICPT) and Novavax (NVAX). Who are Epizyme's key executives? Epizyme's management team includes the following people: Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 51)Mr. Matthew E. Ros, Chief Strategy & Bus. Officer and Principal Financial Officer (Age 52)Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory BoardDr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory BoardMr. Joseph Beaulieu, Controller, Treasurer & Principal Accounting Officer (Age 38) What is Epizyme's stock symbol? Epizyme trades on the NASDAQ under the ticker symbol "EPZM." How do I buy shares of Epizyme? Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Epizyme's stock price today? One share of EPZM stock can currently be purchased for approximately $16.83. How big of a company is Epizyme? Epizyme has a market capitalization of $1.70 billion and generates $23.80 million in revenue each year. The biopharmaceutical company earns $-170,290,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Epizyme employs 124 workers across the globe. View additional information about Epizyme. What is Epizyme's official website? The official website for Epizyme is http://www.epizyme.com/. How can I contact Epizyme? Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected] This page was last updated on 4/9/2020 by MarketBeat.com StaffFeatured Article: What is systematic risk?
